Correlation Between Inhibrx and Unicycive Therapeutics

Can any of the company-specific risk be diversified away by investing in both Inhibrx and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibrx and Unicycive Therapeutics, you can compare the effects of market volatilities on Inhibrx and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Unicycive Therapeutics.

Diversification Opportunities for Inhibrx and Unicycive Therapeutics

0.03

Correlation Coefficient

Inhibrx  Unicycive Therapeutics

Significant diversification

The 3 months correlation between Inhibrx and Unicycive is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of Inhibrx i.e., Inhibrx and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between Inhibrx and Unicycive Therapeutics

Given the investment horizon of 90 days Inhibrx is expected to generate 115.63 times less return on investment than Unicycive Therapeutics. But when comparing it to its historical volatility, Inhibrx is 1.87 times less risky than Unicycive Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Unicycive Therapeutics is currently generating about 0.24 of returns per unit of risk over similar time horizon. If you would invest  32.00  in Unicycive Therapeutics on August 31, 2024 and sell it today you would earn a total of  36.00  from holding Unicycive Therapeutics or generate 112.5% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Inhibrx  vs.  Unicycive Therapeutics

Inhibrx

Risk-Adjusted Performance

0 of 100

Insignificant

Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Unicycive Therapeutics

Risk-Adjusted Performance

19 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Inhibrx and Unicycive Therapeutics

The main advantage of trading using opposite Inhibrx and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.

The idea behind Inhibrx and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.